Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darolutamide SCHEMBL13733117 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL17962572 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL16330936 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL17962599 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL17962573 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL29390245 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL17962596 | 0.93 | AR (1.00) | AR | |
| Darolutamide SCHEMBL29519795 | 0.93 | AR (1.00) | AR | |
| SCHEMBL21250261 | 0.92 | AR (0.89) | AR | |
| SCHEMBL20341041 | 0.90 | AR (0.85) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2016120530-A1 | A CARBOXAMIDE DERIVATIVE AND ITS DIASTEREOMERS IN STABLE CRYSTALLINE FORM | ORION CORPORATION (FI) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190722-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.